[HTML][HTML] When designing vaccines, consider the starting material: the human B cell repertoire

C Havenar-Daughton, RK Abbott, WR Schief… - Current opinion in …, 2018 - Elsevier
C Havenar-Daughton, RK Abbott, WR Schief, S Crotty
Current opinion in immunology, 2018Elsevier
Highlights•Antigen-specific naive human B cell repertoire analysis as clinical trial
prelude.•Protein-specific and epitope-specific quantitation of B cells before antigen
exposure.•B cell precursor frequency and affinity strongly impact germinal center
responses.•Antigen-specific B cell repertoire study informs immunogen design and
prioritization.Most viral vaccines provide protection from infection through the generation of
neutralizing antibodies (nAbs). The repertoire of B cells responding to immunization is the …
Highlights
  • Antigen-specific naive human B cell repertoire analysis as clinical trial prelude.
  • Protein-specific and epitope-specific quantitation of B cells before antigen exposure.
  • B cell precursor frequency and affinity strongly impact germinal center responses.
  • Antigen-specific B cell repertoire study informs immunogen design and prioritization.
Most viral vaccines provide protection from infection through the generation of neutralizing antibodies (nAbs). The repertoire of B cells responding to immunization is the starting material from which nAbs eventually arise. Immunization strategies are increasingly targeting precise B cell specificities to mimic nAbs generated during natural infection, in an effort to maximize the potency of the vaccine-elicited Ab response. An understanding of the human B cell specificities capable of immunogen recognition can aid in immunogen design and inform decision-making for clinical advancement. Here, we review what is known about antigen-specific and epitope-specific naive B cell repertoires in humans and mice, and we consider the challenges for identifying and analyzing antigen-specific naive B cell repertoires. Finally, we provide a framework for further exploration, interpretation, utilization of the B cell repertoire to facilitate vaccine discovery.
Elsevier